Latest Headlines

Latest Headlines

GSK's vaccine unit sees revenue, profit jump in Q3

After struggling out of the gate with Novartis' vaccines in hand, GlaxoSmithKline's vaccines unit turned its fortune in the third quarter and was able to deliver considerable increases in sales and profits.

GlaxoSmithKline's cardio R&D; group records another big PhIII flop

More than a year after its second big Phase III program for darapladib also turned out to be a bust, GlaxoSmithKline is reporting today that losmapimod--cited by CEO Andrew Witty as a top late-stage program--failed to measure up in the first leg of a clinical marathon. And it's not planning to fund step two.